• Login
    View Item 
    •   Home
    • Dudley Group NHS Foundation Trust
    • Staff Publications
    • 2023
    • View Item
    •   Home
    • Dudley Group NHS Foundation Trust
    • Staff Publications
    • 2023
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of West Midlands Evidence RepositoryCommunitiesAuthorsTitlesPublication DateSubjectsPublication TypesJournalPublisherThis CollectionAuthorsTitlesPublication DateSubjectsPublication TypesJournalPublisherProfilesView

    My Account

    LoginRegister

    About

    AboutPolicies Privacy NoticeBlack Country Healthcare NHS Foundation TrustCoventry and Warwickshire Partnership NHS TrustDudley Group NHS Foundation TrustGeorge Eliot Hospital NHS TrustSandwell and West Birmingham NHS TrustSouth Warwickshire University NHS Foundation TrustUniversity Hospitals Birmingham NHS Foundation TrustUniversity Hospitals Coventry and Warwickshire NHS TrustWalsall Healthcare NHS Trust

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Publisher version
    View Source
    Access full-text PDFOpen Access
    View Source
    Check access options
    Check access options
    Author
    Hillmen, Peter
    Pitchford, Alexandra
    Bloor, Adrian
    Broom, Angus
    Young, Moya
    Kennedy, Ben
    Walewska, Renata
    Furtado, Michelle
    Preston, Gavin
    Neilson, Jeffrey R
    Pemberton, Nicholas
    Sidra, Gamal
    Morley, Nicholas
    Cwynarski, Kate
    Schuh, Anna
    Forconi, Francesco
    Elmusharaf, Nagah
    Paneesha, Shankara
    Fox, Christopher P
    Howard, Dena R
    Hockaday, Anna
    Brown, Julia M
    Cairns, David A
    Jackson, Sharon
    Greatorex, Natasha
    Webster, Nichola
    Shingles, Jane
    Dalal, Surita
    Patten, Piers E M
    Allsup, David
    Rawstron, Andrew
    Munir, Talha
    Show allShow less
    Affiliation
    Leeds Teaching Hospitals Trust; The Christie Hospital NHS Foundation Trust; Western General Hospital; The Dudley Group NHS Foundation Trust.
    Publication date
    2023-05-04
    Subject
    Oncology. Pathology.
    
    Metadata
    Show full item record
    Abstract
    The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients considered unfit for fludarabine, cyclophosphamide, and rituximab, the most effective chemoimmunotherapy in CLL. We aimed to assess whether ibrutinib and rituximab is superior to fludarabine, cyclophosphamide, and rituximab in terms of progression-free survival. This study is an interim analysis of FLAIR, which is an open-label, randomised, controlled, phase 3 trial in patients with previously untreated CLL done at 101 UK National Health Service hospitals. Eligible patients were between 18 and 75 years of age with a WHO performance status of 2 or less and disease status requiring treatment according to International Workshop on CLL criteria. Patients with greater than 20% of their CLL cells having the chromosome 17p deletion were excluded. Patients were randomly assigned (1:1) by means of minimisation (Binet stage, age, sex, and centre) with a random element in a web-based system to ibrutinib and rituximab (ibrutinib administered orally at 420 mg/day for up to 6 years; rituximab administered intravenously at 375 mg/m2 on day 1 of cycle 1 and at 500 mg/m2 on day 1 of cycles 2-6 of a 28-day cycle) or fludarabine, cyclophosphamide, and rituximab (fludarabine 24 mg/m2 per day orally on day 1-5, cyclophosphamide 150 mg/m2 per day orally on days 1-5; rituximab as above for up to 6 cycles). The primary endpoint was progression-free survival, analysed by intention to treat. Safety analysis was per protocol. This study is registered with ISRCTN, ISRCTN01844152, and EudraCT, 2013-001944-76, and recruiting is complete. Between Sept 19, 2014, and July 19, 2018, of 1924 patients assessed for eligibility, 771 were randomly assigned with median age 62 years (IQR 56-67), 565 (73%) were male, 206 (27%) were female and 507 (66%) had a WHO performance status of 0. 385 patients were assigned to fludarabine, cyclophosphamide, and rituximab and 386 patients to ibrutinib and rituximab. After a median follow-up of 53 months (IQR 41-61) and at prespecified interim analysis, median progression-free survival was not reached (NR) with ibrutinib and rituximab and was 67 months (95% CI 63-NR) with fludarabine, cyclophosphamide, and rituximab (hazard ratio 0 44 [95% CI 0 32-0 60]; p<0 0001). The most common grade 3 or 4 adverse event was leukopenia (203 [54%] patients in the fludarabine, cyclophosphamide, and rituximab group and 55 [14%] patients in the ibrutinib and rituximab group. Serious adverse events were reported in 205 (53%) of 384 patients receiving ibrutinib and rituximab compared with 203 (54%) of 378 patients receiving fludarabine, cyclophosphamide, and rituximab. Two deaths in the fludarabine, cyclophosphamide, and rituximab group and three deaths in the ibrutinib and rituximab group were deemed to be probably related to treatment. There were eight sudden unexplained or cardiac deaths in the ibrutinib and rituximab group and two in the fludarabine, cyclophosphamide, and rituximab group. Front line treatment with ibrutinib and rituximab significantly improved progression-free survival compared with fludarabine, cyclophosphamide, and rituximab but did not improve overall survival. A small number of sudden unexplained or cardiac deaths in the ibrutinib and rituximab group were observed largely among patients with existing hypertension or history of cardiac disorder.
    Citation
    Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, Walewska R, Furtado M, Preston G, Neilson JR, Pemberton N, Sidra G, Morley N, Cwynarski K, Schuh A, Forconi F, Elmusharaf N, Paneesha S, Fox CP, Howard DR, Hockaday A, Brown JM, Cairns DA, Jackson S, Greatorex N, Webster N, Shingles J, Dalal S, Patten PEM, Allsup D, Rawstron A, Munir T. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 May;24(5):535-552. doi: 10.1016/S1470-2045(23)00144-4.
    Type
    Article
    Handle
    http://hdl.handle.net/20.500.14200/1142
    Additional Links
    http://www.sciencedirect.com/science/journal/14702045
    DOI
    10.1016/S1470-2045(23)00144-4
    PMID
    37142374
    Journal
    The Lancet Oncology
    Publisher
    Elsevier
    ae974a485f413a2113503eed53cd6c53
    10.1016/S1470-2045(23)00144-4
    Scopus Count
    Collections
    Oncology
    2023

    entitlement

    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.